<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00063960</url>
  </required_header>
  <id_info>
    <org_study_id>ACOSOG-Z05032</org_study_id>
    <secondary_id>ACOSOG-Z05032</secondary_id>
    <secondary_id>CDR0000305857</secondary_id>
    <nct_id>NCT00063960</nct_id>
  </id_info>
  <brief_title>Hepatic Arterial Infusion With Floxuridine and Systemic Irinotecan After Surgery in Treating Patients With Hepatic (Liver) Metastases From Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial Of Toxicity Assessment In Two Cohorts Of Patients (Resection Alone Or Ablation With Or Without Resection Of Hepatic Metastases From Colorectal Cancer) Treated With Adjuvant Hepatic Arterial Infusion (HAI) FUDR Plus Systemic CPT-11</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as floxuridine and irinotecan use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Hepatic arterial infusion uses&#xD;
      a catheter to deliver chemotherapy directly to the liver. Combining more than one drug and&#xD;
      giving them in different ways may kill any tumor cells remaining after surgery.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of systemic irinotecan and hepatic&#xD;
      arterial infusion with floxuridine after surgery in treating patients who have hepatic&#xD;
      (liver) metastases from colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity of hepatic arterial infusion with floxuridine and systemic&#xD;
           irinotecan adjuvant to liver metastases resection or ablation with or without resection&#xD;
           in patients with hepatic metastases secondary to colorectal cancer.&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to any hepatic recurrence or progression in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to prior therapy&#xD;
      (liver metastases resection only vs ablation with or without resection).&#xD;
&#xD;
      Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial&#xD;
      infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1&#xD;
      and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to hepatic recurrence or progression</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>floxuridine + irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.&#xD;
Patients are followed every 3 months for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
    <arm_group_label>floxuridine + irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>floxuridine + irinotecan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma&#xD;
&#xD;
               -  Primary colorectal adenocarcinoma that has been completely resected (R0 disease)&#xD;
&#xD;
                    -  No evidence of residual, viable tumor by abdominal/pelvic helical CT scan or&#xD;
                       MRI with IV contrast&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
                    -  No more than 9 liver metastases&#xD;
&#xD;
                    -  All lesions completely resected or completely treated by ablation (with or&#xD;
                       without resection)&#xD;
&#xD;
                         -  All lesions treated by ablation must have been less than 5 cm in size&#xD;
                            and at least 5 mm away from main/left/right portal vein, common bile&#xD;
                            duct, and inferior vena cava&#xD;
&#xD;
                         -  All resected lesions must have a negative surgical margin (R0)&#xD;
&#xD;
          -  Disease progression after prior systemic irinotecan for metastatic disease allowed&#xD;
&#xD;
          -  No extrahepatic metastases confirmed by chest CT scan except colorectal mesenteric&#xD;
             lymph node metastases resected at the time of primary tumor resection&#xD;
&#xD;
               -  No other prior resection of extrahepatic metastases&#xD;
&#xD;
          -  Must have the entire liver remnant perfused with a single catheter&#xD;
&#xD;
          -  Must have a nuclear medicine macro-aggregated albumin flow scan to confirm the area of&#xD;
             pump perfusion before study registration&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT no greater than 2.0 times ULN&#xD;
&#xD;
          -  No active hepatitis B or C infection&#xD;
&#xD;
          -  No histological evidence of cirrhosis&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Calcium less than 1.3 times ULN&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
               -  Postmenopausal women must be amenorrheic for at least 12 consecutive months to be&#xD;
                  deemed not fertile&#xD;
&#xD;
          -  Medically fit to begin chemotherapy between 4 and 8 weeks after surgery&#xD;
&#xD;
          -  Prior cancer allowed if all of the following criteria are met:&#xD;
&#xD;
               -  Undergone potentially curative therapy for all prior malignancies&#xD;
&#xD;
               -  No other malignancy within the past 5 years except the following:&#xD;
&#xD;
                    -  Effectively treated basal cell or squamous cell skin cancer&#xD;
&#xD;
                    -  Carcinoma in situ of the cervix that has been effectively treated by surgery&#xD;
                       alone&#xD;
&#xD;
                    -  Lobular carcinoma in situ of the ipsilateral or contralateral breast treated&#xD;
                       by surgery alone&#xD;
&#xD;
               -  No evidence of recurrence of any prior malignancy&#xD;
&#xD;
          -  No prior hepatic arterial infusion pump malfunction, malperfusion, or infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunologic or biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy within 4 weeks before hepatic resection or hepatic ablation&#xD;
             (with or without resection)&#xD;
&#xD;
          -  No prior hepatic arterial infusion with fluorouracil or floxuridine&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No concurrent adjuvant radiotherapy to the pelvis&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuman Fong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Baptist Hospital</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503-9985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integris Oncology Services</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Group</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908-4735</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

